

## **CTSA Begins Treating Patients with the Axxent® Electronic Brachytherapy, eBx™, System from Xoft, Inc.; to Lead Clinical Trial**



June 25, 2009

Cancer Treatment Services Arizona (CTSA) has begun treating cancer patients using the Axxent® Electronic Brachytherapy, eBx™, System from Xoft, Inc. Electronic Brachytherapy, eBx™, delivers a high therapeutic dose to a cancer tumor while sparing nearby normal tissue by using a miniaturized X-ray source rather than radioactive isotopes. The Xoft system will offer CTSA's patients an additional treatment option for early stage breast cancer, endometrial cancer, and skin cancer. Treatment can be performed without the need for a shielded room, allowing the radiation oncologist and other medical personnel to be present during treatment delivery and minimizing patient anxiety.

In addition, CTSA's Dr. Ajay Bhatnagar has been named the principal investigator of a multi-center skin cancer trial to prove the Axxent® Electronic Brachytherapy, eBx™, System's safety and feasibility for the treatment of non-melanoma skin cancers. Skin cancer is the most common cancer in the United States with more than 1 million cases diagnosed annually and results in more than 10,000 deaths each year, according to the National Cancer Institute. However, if diagnosed and treated early, most cases of skin cancer can be cured. While melanoma is the most serious form of skin cancers, it accounts for less than 10 percent of all cases. Non-melanoma skin cancers, such as basal cell carcinoma and squamous cell carcinoma, represent the majority of all new cases.

"I am very excited to be the principal investigator for the first clinical study utilizing Xoft's Electronic Brachytherapy for surface treatment of non-melanoma skin cancers," said Dr. Ajay Bhatnagar. "Since skin cancers usually present on areas exposed to the sun frequently, such as the face, head and neck, we have to consider both the eradication of the cancer as well as cosmetic outcomes when determining the best treatment option for the patient."

The prospective study is designed to gather data to enable physicians to develop guidelines for treating skin cancer patients with electronic brachytherapy that will result in the best patient outcomes. Treatment options for non-melanoma skin cancer typically include surgical excision, Mohs micrographic surgery, which involves removing tissue in very thin layers for pathological evaluation, and radiation therapy. The location of the cancer and the extent of the disease impacts which treatment option is best for each patient.

"Through its use in the treatment of breast and endometrial cancers, electronic brachytherapy has shown the proven ability to deliver a high treatment dose to a cancer tumor while sparing nearby normal tissue similar to that of the standard Ir-192 HDR brachytherapy, but using a

miniaturized X-ray treatment source allows this treatment to be used in nearly any clinical exam room which has many advantages for both the patient and the clinician..The ability to treat with little impact on surrounding normal tissues should allow for an excellent cosmetic outcome as well as a high chance of treatment success with skin cancer. Therefore, this study is extremely vital and will help our field gain more credibility in the world of skin cancer including the dermatologists.” added Dr. Bhatnagar.

#### Contact Information

Cancer Treatment Services Arizona

1876 East Sabin Drive, Suite 10

Casa Grande, AZ 85222

*p.* (520) 836-9800

*f.* (520) 836-1510

*e.* [casagrande@cancertreatmentservices.com](mailto:casagrande@cancertreatmentservices.com)

#### About Cancer Treatment Services International, L.P.

Cancer Treatment Services International L.P. (CTSI L.P) is a provider of comprehensive treatment for cancer patients with a main focus on medical oncology and radiation oncology. The company was founded by a core group of physicians and businessmen with substantial experience in the development, operation and networking of cancer services on a national and international level. CTSI is able to provide innovative and technologically-advanced treatment solutions to areas of the world where therapy is currently inadequate in either quality or capacity. The company currently operates clinics and has development projects both in the U.S. and internationally.

<http://www.cancertreatmentservices.com>